Recursion Pharmaceuticals (RXRX) Assets Average (2021 - 2026)

Recursion Pharmaceuticals' Assets Average history runs 6 years deep, the most recent figure standing at $1.4 billion for Q1 2026.

• Quarterly Assets Average rose 2.17% year-over-year to $1.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 2.17% YoY) and the FY2025 annual result came in at $1.5 billion, up 39.03% from the prior year.
• Assets Average was $1.4 billion for Q1 2026 at Recursion Pharmaceuticals, down from $1.4 billion in the prior quarter.
• Across five years, Assets Average topped out at $1.4 billion in Q4 2025 and bottomed at $605.8 million in Q1 2024.
• A 5-year average of $897.8 million and a median of $672.3 million in 2022 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average surged 135.69% — and 2024, when it fell 8.81%.
• Recursion Pharmaceuticals' Assets Average stood at $656.4 million in 2022, then declined by 2.16% to $642.3 million in 2023, then surged by 69.33% to $1.1 billion in 2024, then soared by 32.12% to $1.4 billion in 2025, then fell by 2.09% to $1.4 billion in 2026.
• Business Quant data shows RXRX's Assets Average at $1.4 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.4 billion in Q3 2025.